Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMET12 and Toripalimab Combined Chemotherapy in EGFR Positive Advanced NSCLC
NCT06208033Phase 1Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jan 2024
- Primary completion
- Oct 2024
- Modality
- Bispecific Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of SMET12 in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: incidence of adverse events at 1 year, rate of adverse events at 1 year and 1 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
SMET12
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06208033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208033.